Drug Trial Radar · NCT06998706
REGEND001 Autologous Basal Layer Stem Cell Transplantation for Interstitial Lung Disease (ILD): A Translational Application Study
Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Jun 19, 2025
Primary completion
Jun 30, 2029
Study completion Jun 30, 2029
Sponsor
- Lead sponsor
- Ruijin HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 31, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial evaluates the safety and efficacy of REGEND001, an autologous bronchial basal layer stem cell therapy, in patients with interstitial lung disease (ILD). The treatment involves harvesting the patient's own stem cells (expressing KRT5/P63 markers), expanding them ex vivo, and administering them via bronchoscopic infusion to regenerate damaged lung tissue.
Conditions
- Interstitial Lung Disease (ILD)
Interventions
REGEND001 Autologous Basal Layer Stem Cell SuspensionBiological
REGEND001 Autologous Basal Layer Stem Cell Suspension is an innovative cell therapy product designed for chronic structural lung diseases, such as bronchiectasis. This treatment involves harvesting regenerative stem cells (expressing KRT5/P63 markers) from the patient's own bronchial basal layer via fiberoptic bronchoscopy. After isolation, purification, and ex vivo expansion, the cells are administered as a suspension through bronchoscopic infusion into damaged lung segments.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in DLCO from baseline.Time frame: Baseline, 4 weeks post treatment, 24 weeks post treatment
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Ruijin Hospital Hainan Branch, Shanghai Jiao Tong University School of Medicine
Qionghai, Hainan, China · Recruiting
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.